IMUC
vs
S&P 500
IMUC
S&P 500
Over the past 12 months, IMUC has underperformed S&P 500, delivering a return of -12% compared to the S&P 500's +14% growth.
Stocks Performance
IMUC vs S&P 500
Performance Gap
IMUC vs S&P 500
Performance By Year
IMUC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ImmunoCellular Therapeutics Ltd
Glance View
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company is headquartered in Westlake Village, California and currently employs 4 full-time employees. The company went IPO on 2006-09-19. The firm is developing immune-based therapies for the treatment of cancers. The firm's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. The company is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.
